FDA Clears Processa Study for Chronic Hives Drug
Regulators approved a Phase 2 trial for VT-7208 to treat adults with chronic spontaneous urticaria.
Updated on Oct. 29, 2026 in Allergies
Live Poll
Do you consider the expansion of clinical-stage pharmaceutical companies a positive sign for future medical treatment options?
Processa Pharmaceuticals received FDA clearance for an investigational new drug application to begin a Phase 2 study of VT-7208. The company intends to test the drug in adults suffering from moderate-to-severe chronic spontaneous urticaria.
Why it matters
The company aims to diversify its immunology pipeline by developing a therapeutic alternative to existing injectable FcRn treatments. This move addresses a condition currently impacting an estimated 1.6 to 2 million adults across the United States.
The planned multicenter, randomized study will evaluate VT-7208 versus placebo over a 12-week period. The trial will focus on a sample size of approximately 120 adults with moderate-to-severe disease.
The players
Processa Pharmaceuticals
This is a Vero Beach-based pharmaceutical company focused on expanding its immunology pipeline.
Sheila Gujrathi
She serves as the Executive Chair of the Board of Directors for Processa Pharmaceuticals.
Generian Pharmaceuticals
This is a biotech firm that has entered into a research collaboration and exclusive option agreement with Processa.
The details
In addition to the study launch, Processa entered a research collaboration with Generian Pharmaceuticals and appointed Sheila Gujrathi as Executive Chair of the Board of Directors. The company plans to follow this trial with additional Phase 2 studies for VT-7208 targeting food allergies and relapsing multiple sclerosis.
Timeline
June 2026: Sheila Gujrathi joined the board following the acquisition of Vidya Therapeutics.
October 29, 2026: The FDA cleared the investigational new drug application for the study.
Second half of 2029: Current cash resources are expected to sustain company operations.
The Big Picture
This development reflects an ongoing shift within the immunology sector to challenge the dominance of established FcRn therapies. By pursuing a novel candidate for chronic spontaneous urticaria, Processa seeks to carve out market share from current standard-of-care treatments.
The initiation of this Phase 2 study offers potential hope for patients who have not found success with existing injectable therapies. While the study is in early stages, successful results could eventually provide new treatment options for those managing moderate-to-severe hives.
The takeaway
This trial marks a strategic effort by the company to expand its presence in the immunology market. Patients and healthcare providers should monitor future study milestones to see if this candidate offers a viable alternative to currently available drugs.
Further reading
For more information on the latest research and advancements in this field, visit the Allergies section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you consider the expansion of clinical-stage pharmaceutical companies a positive sign for future medical treatment options?
